Rare EGFRm NSCLC: More First-Line Options Emerge

Area of Science:

• Oncology
• Medical Research

Background:

• Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions presents treatment challenges.
• Current later-line therapies for NSCLC with EGFR exon 20 insertions have limitations.

Purpose of the Study:

• To evaluate sunvozertinib as a first-line treatment for NSCLC with EGFR exon 20 insertions.
• To assess the efficacy of amivantamab combined with lazertinib in patients with atypical EGFR mutations.

Main Methods:

• Phase III WU-KONG28 trial comparing sunvozertinib to chemotherapy.
• Analysis of updated CHRYSALIS-2 trial data for amivantamab and lazertinib combination therapy.

Main Results:

• Sunvozertinib demonstrated superior efficacy compared to chemotherapy in the upfront setting for NSCLC with EGFR exon 20 insertions.
• Amivantamab plus lazertinib showed initial efficacy translating to durable overall survival in patients with atypical EGFR mutations.

Conclusions:

• Sunvozertinib is a potential effective upfront treatment for NSCLC harboring EGFR exon 20 insertions.
• Amivantamab and lazertinib combination therapy represents a novel therapeutic option for atypical EGFR mutations in NSCLC.